{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:36:55Z","timestamp":1792773415815,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clon.2026.104340","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:40:39Z","timestamp":1788849639000},"page":"104340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Final Results From a Phase I Dose Escalation Study (DESTROY-1) in Stereotactic Boost After Prior Radiotherapy"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1276-5070","authenticated-orcid":false,"given":"F.","family":"Deodato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1169","authenticated-orcid":false,"given":"D.","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bonome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buwenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-201X","authenticated-orcid":false,"given":"G.","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clon.2026.104340_bib1","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0360-3016(03)00743-0","article-title":"Potential for reduced toxicity and dose escalation in the treatment of inoperable non-small-cell lung cancer: a comparison of intensity-modulated radiation therapy (IMRT), 3D conformal radiation, and elective nodal irradiation","volume":"57","author":"Grills","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104517","article-title":"Stereotactic body radiotherapy boost as an alternative to brachytherapy for cervical cancer: A scoping review","volume":"204","author":"Miranda","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clon.2026.104340_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.phro.2018.08.003","article-title":"Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET\/CT","volume":"7","author":"Meijer","year":"2018","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"11","key":"10.1016\/j.clon.2026.104340_bib5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jtho.2017.07.036","article-title":"Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study","volume":"12","author":"Higgins","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.clon.2026.104340_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S1470-2045(24)00320-6","article-title":"Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial","volume":"25","author":"Vera","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104340_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110439","article-title":"Stereotactic ablative radiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis","volume":"201","author":"Viani","year":"2024","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13014-022-01981-z","article-title":"MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience","volume":"17","author":"Hadi","year":"2022","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tjog.2020.11.017","article-title":"Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy","volume":"60","author":"Cheng","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"1094","key":"10.1016\/j.clon.2026.104340_bib10","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20180422","article-title":"Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial","volume":"92","author":"Deodato","year":"2019","journal-title":"Br J Radiol"},{"issue":"10","key":"10.1016\/j.clon.2026.104340_bib11","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.clon.2023.07.011","article-title":"Stereotactic Body Reirradiation in Gynaecological Cancer: Outcomes and Toxicities from a Single Institution Experience","volume":"35","author":"Macchia","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.clon.2026.104340_bib12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clon.2026.104340_bib14","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.clon.2026.104340_bib15","article-title":"Stereotactic radiosurgery (SRS) with volumetric modulated arc therapy (VMAT): interim results of a multi-arm phase I trial (DESTROY-2)","volume":"26","author":"Deodato","year":"2014","journal-title":"Clin Oncol (R Coll Radiol"},{"key":"10.1016\/j.clon.2026.104340_bib16","doi-asserted-by":"crossref","unstructured":"Deodato F, Ferro M, Cilla S, Ianiro A, Buwenge M, Re A, et al. Stereobody radiotherapy for nodal recurrences in oligometastatic patients: a pooled analysis from two phase I clinical trials. Clin Exp Metastasis 2020 Aug;37(4):519\u2013529. https:\/\/doi.org\/10.1007\/s10585-020-10039-x. Epub 2020 Jun 3. PMID: 32495238.","DOI":"10.1007\/s10585-020-10039-x"},{"key":"10.1016\/j.clon.2026.104340_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102573","article-title":"Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: A systematic review","volume":"118","author":"Allignet","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clon.2026.104340_bib18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2008.01.054","article-title":"Once-Weekly, High-Dose Stereotactic Body Radiotherapy for Lung Cancer: 6-Year Analysis of 60 Early-Stage, 42 Locally Advanced, and 7 Metastatic Lung Cancers","volume":"72","author":"Salazar","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.ijrobp.2012.11.011","article-title":"Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study","volume":"85","author":"Feddock","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/1748-717X-8-179","article-title":"Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer","volume":"8","author":"Karam","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2026.104340_bib21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study","volume":"96","author":"Hepel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2016.06.374","article-title":"An Update on Results Regarding a Prospective Study of SBRT for Post-chemoradiation Residual Disease in Stage II\/III Non-small Cell Lung Cancer","volume":"96","author":"Kumar","year":"2016","journal-title":"Int J Radiat Oncology Biology Physics"},{"key":"10.1016\/j.clon.2026.104340_bib23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.07.036","article-title":"Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II\/III Non-Small Cell Lung Cancer","volume":"99","author":"Kumar","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.radonc.2018.03.024","article-title":"Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial","volume":"127","author":"Doyen","year":"2018","journal-title":"Radiother Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104340_bib25","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/curroncol28050324","article-title":"Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14)","volume":"28","author":"Martel-Lafay","year":"2021","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13014-018-1071-5","article-title":"Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies","volume":"13","author":"Kim","year":"2018","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2026.104340_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7785\/tcrt.2012.500425","article-title":"Outcome Study of Cobalt Based Stereotactic Body Radiation Therapy for Patients with Inoperable Stage III Non-small Cell Lung Cancer","volume":"14","author":"Wang","year":"2015","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijrobp.2019.10.042","article-title":"A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer","volume":"106","author":"Albuquerque","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl","key":"10.1016\/j.clon.2026.104340_bib29","doi-asserted-by":"crossref","first-page":"A23","DOI":"10.1136\/ijgc-2022-ESGO.52","article-title":"2022- RA-721-ESGO Clinical outcomes of SBRT boost to the cervix as an alternative to intracavitary brachytherapy in locally advanced cervical cancer: retrospective analysis from the West of Scotland","volume":"A2","author":"Amali","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.brachy.2011.12.001","article-title":"Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer","volume":"11","author":"Cengiz","year":"2012","journal-title":"Brachytherapy"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tjog.2020.11.017","article-title":"Stereotactic body radiotherapy for pelvic boost in gynecological cancer patients with local recurrence or unsuitable for intracavitary brachytherapy","volume":"60","author":"Cheng","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.clon.2026.104340_bib32","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1136\/ijgc-2019-001104","article-title":"Non-invasive stereotactic ablative boost in patients with locally advanced cervical cancer","volume":"30","author":"Dalwadi","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib33","first-page":"53","article-title":"Stereotactic body radiation therapy boost in patients with cervical cancer ineligible for brachytherapy. Cancer Diagn","volume":"1","author":"Facondo","year":"2021","journal-title":"Progn"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib34","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/curroncol29020079","article-title":"Advances in radiation oncology for the treatment of cervical cancer","volume":"29","author":"Faye","year":"2022","journal-title":"Curr Oncol Tor Ont"},{"issue":"9284","key":"10.1016\/j.clon.2026.104340_bib35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0140-6736(01)05965-7","article-title":"Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis","volume":"358","author":"Green","year":"2001","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2020.07.2615","article-title":"Stereotactic body radiotherapy as a boost in cervical cancer: a single-center experience","volume":"108","author":"Gultekin","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2012.00025","article-title":"CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy","volume":"2","author":"Haas","year":"2012","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13014-022-01981-z","article-title":"MR-guided SBRT boost for patients with locally advanced or recurrent gynecological cancers ineligible for brachytherapy: feasibility and early clinical experience","volume":"17","author":"Hadi","year":"2022","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.clon.2026.104340_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/OTT.S40370","article-title":"Stereotactic body radiation therapy via helical tomotherapy to replace brachytherapy for brachytherapy-unsuitable cervical cancer patients - a preliminary result","volume":"6","author":"Hsieh","year":"2013","journal-title":"OncoTargets Ther"},{"issue":"9","key":"10.1016\/j.clon.2026.104340_bib40","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/jjco\/hyz074","article-title":"Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study","volume":"49","author":"Ito","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib41","article-title":"Stereotactic body radiotherapy as an alternative to brachytherapy in gynecologic cancer","volume":"2013","author":"Kubicek","year":"2013","journal-title":"BioMed Res Int"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13014-021-01877-4","article-title":"Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible","volume":"16","author":"Lee","year":"2021","journal-title":"Radiat Oncol"},{"issue":"21","key":"10.1016\/j.clon.2026.104340_bib43","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1002\/cncr.33795","article-title":"Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years","volume":"127","author":"Lin","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clon.2026.104340_bib44","doi-asserted-by":"crossref","first-page":"207 (May","DOI":"10.21037\/atm.2017.03.102","article-title":"External beam techniques to boost cervical cancer when brachytherapy is not an option\u2014theories and applications","volume":"5","author":"Mahmoud","year":"2017","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2015.07.484","article-title":"Stereotactic body radiation therapy as a boost alternative to brachytherapy for primary gynecologic cancer: disease control and quality of life outcomes from a phase II Trial","volume":"93","author":"Mantz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib46","article-title":"Population-Based Trends in Cervical Cancer Incidence and Mortality in Brazil: Focusing on Black and Indigenous Population Disparities","volume":"17","author":"de Melo","year":"2023","journal-title":"J Racial Ethn Health Disparities"},{"issue":"6","key":"10.1016\/j.clon.2026.104340_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00066-020-01685-x","article-title":"Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer","volume":"197","author":"Morgenthaler","year":"2021","journal-title":"Strahl Onkol Organ Dtsch Rontgengesellschaft Al"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/IGC.0000000000001200","article-title":"Stereotactic body radiation therapy, intensity-modulated radiation therapy, and brachytherapy boost modalities in invasive cervical cancer: a study of the national cancer data base","volume":"28","author":"O\u02bcDonnell","year":"2018","journal-title":"Int J Gynecol Cancer J Int Gynecol Cancer Soc"},{"key":"10.1016\/j.clon.2026.104340_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.lungcan.2020.06.017","article-title":"What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?","volume":"146","author":"Nicosia","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.clon.2026.104340_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110278","article-title":"Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer","volume":"196","author":"Chen","year":"2024","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib51","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.radonc.2017.09.030","article-title":"Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review","volume":"125","author":"Murray","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2026.104340_bib52","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2023.10.016","article-title":"Outcomes and toxicity in re-irradiation of gynecologic cancer: Systematic review of the Italian association of radiation and clinical oncology (AIRO)","volume":"179","author":"Critelli","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104340_bib53","article-title":"Salvage stereotactic body radiotherapy for locally recurrent uterine cervix cancer at the pelvic sidewall: feasibility and complication","volume":"12","author":"Seo","year":"2016","journal-title":"Asia Pacif J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3\/RAD Phase II Trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2026.104340_bib55","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2025.03.032","article-title":"Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3\/RAD)","volume":"123","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.clon.2026.104340_bib56","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/CAD.0000000000001684","volume":"36","author":"Macchia","year":"2025","journal-title":"Anticancer Drugs"},{"issue":"5","key":"10.1016\/j.clon.2026.104340_bib57","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ijrobp.2024.12.030","article-title":"In Reply to Gurlek et al","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2026.104340_bib58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2024.01.023","article-title":"Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer","volume":"184","author":"Macchia","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526003110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526003110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T15:06:14Z","timestamp":1792767974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526003110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":58,"alternative-id":["S0936655526003110"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104340","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final Results From a Phase I Dose Escalation Study (DESTROY-1) in Stereotactic Boost After Prior Radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104340"}}